Sivik Global Healthcare LLC Sells 5,000 Shares of McKesson Co. (NYSE:MCK)

Sivik Global Healthcare LLC lessened its position in shares of McKesson Co. (NYSE:MCK) by 25.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 15,000 shares of the company’s stock after selling 5,000 shares during the quarter. McKesson comprises approximately 4.5% of Sivik Global Healthcare LLC’s portfolio, making the stock its 4th largest position. Sivik Global Healthcare LLC’s holdings in McKesson were worth $8,549,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC lifted its stake in McKesson by 742.9% during the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company’s stock worth $29,000 after purchasing an additional 52 shares in the last quarter. MidAtlantic Capital Management Inc. acquired a new position in McKesson in the 3rd quarter valued at about $29,000. RPg Family Wealth Advisory LLC purchased a new stake in McKesson during the third quarter worth about $31,000. Synergy Asset Management LLC acquired a new stake in shares of McKesson during the fourth quarter worth about $32,000. Finally, Crews Bank & Trust acquired a new position in shares of McKesson in the fourth quarter valued at approximately $33,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

McKesson Price Performance

Shares of McKesson stock opened at $605.70 on Thursday. The business has a 50 day moving average price of $592.16 and a 200 day moving average price of $561.52. The company has a market capitalization of $76.89 billion, a P/E ratio of 31.33, a P/E/G ratio of 1.26 and a beta of 0.52. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $637.51.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, beating the consensus estimate of $6.88 by $0.19. The firm had revenue of $93.65 billion during the quarter, compared to the consensus estimate of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The firm’s revenue for the quarter was up 21.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.23 EPS. As a group, research analysts expect that McKesson Co. will post 32.73 EPS for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.47%. McKesson’s payout ratio is 14.71%.

Insider Buying and Selling

In other news, EVP Leann B. Smith sold 579 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the completion of the sale, the executive vice president now owns 864 shares of the company’s stock, valued at $494,890.56. This represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.11% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MCK shares. Bank of America cut their price objective on McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Evercore ISI upped their target price on shares of McKesson from $560.00 to $680.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Wells Fargo & Company boosted their price target on shares of McKesson from $535.00 to $641.00 and gave the stock an “equal weight” rating in a report on Friday, December 13th. StockNews.com raised shares of McKesson from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Finally, Baird R W upgraded shares of McKesson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $646.14.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.